By Derrick Stanley
The Minnesota Department of Health is adding post traumatic stress disorder (PTSD) to its list of conditions that can qualify patients for medical marijuana.
Minnesota now joins New Jersey, Michigan, California, Illinois, Connecticut, Delaware, Maine, Massachusetts, New Mexico, Arizona, Washington, Rhode Island and Oregon as states that allow those with PTSD to legally use medical cannabis.
A large amount of research has led to the conclusion that medical marijuana can be useful for "innovative intervention strategies (e.g. pharmacological enhancement of exposure-based therapy) in PTSD and other fear learning-related disorders,” according to a government-funded study released in 2014.
Another study released in 2015 found that; “When inhaled or delivered orally or transdermally, cannabinoids (the psychoactive components of unrefined marijuana and various derivative products) activate endogenous cannabinoid receptors, modulating neurotransmitter release and producing a wide range of central nervous system effects, including increased pleasure and alteration of memory processes…. Those effects provide a pharmacologic rationale for the use of cannabinoids to manage the three core PTSD symptom clusters: reexperiencing, avoidance and numbing, and hyperarousal.”